EP方案配合参芪扶正注射液对小细胞肺癌患者RECIST及KPS评分的影响研究

Clinical research of EP regimen with the Shenqi Fuzheng injectiontreatment on small cell lung cancer about RECIST and KPS score

目的观察EP方案配合参芪扶正注射液对小细胞肺癌患者实体瘤客观疗效评定标准(RECIST)及生活质量(KPS评分)的影响。方法将90例小细胞肺癌患者随机分为观察组与对照组,均予相应化疗方案,观察组加用参芪扶正注射液;两组均以21d为1周期,2个周期后评判疗效。结果观察组患者临床疗效优于对照组,但无显著性差异(P>0.05)。观察组在生活质量、化疗毒副反应改善等方面明显优于对照组(P<0.05)。结论参芪扶正注射液辅助化疗能改善小细胞肺癌患者的生活质量,减少并发症,值得临床推广应用。

Objective To observe the clinical efficacy of the SFI fluid adjuvant therapy of small cell lung cancer about RECIST and KPS score. Methods 90 cases of small cell lung cancer patients were randomly divided into observation group and control group, Both groups were treated with chemotherapy, the observation group were given the SFI,21 d was a cycle, judge the efficacy after two cycles. Results The clinical efficacy of the observe group of patients was better than that of the control group, but there was no significant difference （ P 〉 0. 05 ）. The quality of life and the improvement of side effects of the observation group was obviously supe- rior to that of the control group. Conclusion The SFI liquid adjuvant chemotherapy can improve the life quality of patients with small cell lung cancer, and certain attenuated synergies and worthy of clinical application.